Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

Company Overview

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Key Stats

• Today's Range: $25.60 to $26.50
• 50-Day Range: $21.84 to $26.16
• 52-Week Range: $20.92 to $42.48
• Volume: 924,136 shs
• Average Volume: 283,096 shs
• Market Capitalization: $49.54 billion
• P/E Ratio: 30.19
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DSNKY Stock Analysis - Frequently Asked Questions

How have DSNKY shares performed this year?

Daiichi Sankyo's stock was trading at $27.29 at the beginning of 2025. Since then, DSNKY stock has decreased by 4.9% and is now trading at $25.96.
View the best growth stocks for 2025 here.

How were Daiichi Sankyo's earnings last quarter?

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) announced its earnings results on Friday, April, 25th. The company reported $0.30 EPS for the quarter. The firm earned $3.40 billion during the quarter. Daiichi Sankyo had a net margin of 13.62% and a trailing twelve-month return on equity of 14.53%.

How do I buy shares of Daiichi Sankyo?

Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 4/25/2025
• Today: 5/19/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:DSNKY
• Previous Symbol: OTCMKTS:DSNKY
• CIK: N/A
• Web: www.daiichisankyo.com
• Phone: (136) 225-1111
• Fax: N/A
• Employees: 17,435
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $1.03
• Trailing P/E Ratio: 28.23
• Forward P/E Ratio: 33.26
• P/E Growth: 1.72
• Net Income: $1.39 billion
• Net Margins: 13.62%
• Pretax Margin: N/A
• Return on Equity: 14.53%
• Return on Assets: 7.07%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 2.77
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: $11.09 billion
• Price / Sales: 4.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.62 per share
• Price / Book: 4.32

Miscellaneous

• Outstanding Shares: 1,908,322,000
• Free Float: N/A
• Market Cap: $46.33 billion
• Optionable: Not Optionable
• Beta: N/A